Meet the Annuity Trust on Bernie Sanders Hit List
How to Get Medicaid for Nursing Home Care Without Going Broke
10 States Where the Millennials Are More Obese Than the Seniors
The $475,000 price tag on Novartis AG’s latest breakthrough cancer therapy came under fire from one of the biggest managers of drug costs in the United States, underscoring the challenges the Swiss drugmaker will face in promoting the potential blockbuster.
The cost of the leukemia treatment, called Kymriah, is “dramatically higher” than other such complex treatments, and the health care system isn’t ready to pay for it, Steve Miller, chief medical officer at Express Scripts Holding Co., said Thursday in a blog post on his company’s website. Gene therapies like Novartis’s are targeted at a small number of patients and typically used just once, meaning that drug companies have limited chances to recoup their investment.
“Therein lies the challenge,” Miller wrote. “We need a new payment model.”
Top 10 Medical Stocks To Invest In Right Now: Aqua America, Inc.(WTR)
Advisors’ Opinion:
- [By Ethan Ryder]
Connecticut Water Service (NASDAQ: CTWS) and Aqua America (NYSE:WTR) are both utilities companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
- [By ]
Cramer was bearish on United States Steel (X) , Teva Pharmaceuticals (TEVA) , Aqua America (WTR) and Mueller Water Products (MWA) .
Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.
- [By Shane Hupp]
Duff & Phelps Investment Management Co. reduced its stake in shares of Aqua America (NYSE:WTR) by 7.1% during the first quarter, Holdings Channel reports. The institutional investor owned 95,640 shares of the utilities provider’s stock after selling 7,290 shares during the quarter. Duff & Phelps Investment Management Co.’s holdings in Aqua America were worth $3,257,000 at the end of the most recent quarter.
- [By Ethan Ryder]
ValuEngine upgraded shares of Aqua America (NYSE:WTR) from a hold rating to a buy rating in a report released on Friday.
Several other analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of Aqua America from a hold rating to a buy rating and set a $41.00 price objective on the stock in a research report on Monday, January 15th. Wells Fargo downgraded shares of Aqua America from an outperform rating to a market perform rating and dropped their price target for the stock from $43.00 to $37.00 in a research report on Monday, February 26th. UBS began coverage on shares of Aqua America in a research report on Thursday, March 8th. They set a neutral rating and a $36.00 price target on the stock. Finally, Boenning Scattergood restated a neutral rating on shares of Aqua America in a research report on Tuesday, April 24th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $38.29.
- [By Joseph Griffin]
Aqua America (NYSE: WTR) and SJW Group (NYSE:SJW) are both utilities companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.
- [By ]
Aqua America (WTR) : “This is not the stock for a hot economy, even though this is a well-run company.”
Mueller Water Products (MWA) : “This is not the time to buy. I don’t like the numbers.”
Top 10 Medical Stocks To Invest In Right Now: HealthEquity, Inc.(HQY)
Advisors’ Opinion:
- [By Brian Feroldi]
For example, I used finvizin the recent past to find a dynamic growth company called HealthEquity (NASDAQ:HQY). I quickly learned that HealthEquity’s revenue and earnings have compounded at 38% and 57%, respectively, over the last five years. Those numbers convinced me to dig deeper and I soon became so excited about the company’s prospects that I purchased shares for myself right away.
- [By Max Byerly]
Swiss National Bank grew its holdings in HealthEquity (NASDAQ:HQY) by 3.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,800 shares of the company’s stock after purchasing an additional 2,900 shares during the quarter. Swiss National Bank owned approximately 0.15% of HealthEquity worth $5,376,000 at the end of the most recent quarter.
- [By Brian Feroldi]
So where am I going to invest my capital? While I’m still refining my list, here are seven stocks that I currently own that I’m strongly considering adding to:
Hubspot (NYSE: HUBS) — A software-as-a-service provider that is pioneering the shift toward “inbound” marketing. HealthEquity (NASDAQ: HQY) — A fast-growing company focused on Health Savings Accounts that boasts three sources of recurring revenue. Axon Enterprise (NASDAQ: AAXN) — The leading provider ofTaser stun guns, law enforcement body cameras, and evidence-management software. Paycom Software (NYSE: PAYC) — A founder-ledpayroll-processor company that is gobbling up market share. Adobe Systems (NASDAQ: ADBE)– The company’s push to the cloud is drivingdouble-digitgains in revenue and profits. AppFolio (NASDAQ: APPF) — Asoftware-as-a-service provider focused on servicing business owners in severalniche markets. BlackLine (NASDAQ: BL) — A software company that is attempting to bring the accounting process into the 21st century.
All seven of these businesses are poised to deliver double-digit organic revenue and profit growth over the next five years. That’s a prospect I find quite enticing, and I think the odds are very favorable that they’ll outperform Apple as a group from here.
- [By Max Byerly]
ValuEngine upgraded shares of HealthEquity (NASDAQ:HQY) from a buy rating to a strong-buy rating in a research report report published on Tuesday morning.
- [By Max Byerly]
Healthequity Inc (NASDAQ:HQY) – Research analysts at Barrington Research issued their Q2 2019 EPS estimates for shares of Healthequity in a report issued on Tuesday, June 5th. Barrington Research analyst A. Paris. Jr expects that the company will post earnings per share of $0.20 for the quarter. Barrington Research currently has a “Outperform” rating and a $85.00 target price on the stock. Barrington Research also issued estimates for Healthequity’s FY2019 earnings at $0.70 EPS.
Top 10 Medical Stocks To Invest In Right Now: Genesis Energy, L.P.(GEL)
Advisors’ Opinion:
- [By Joseph Griffin]
Stifel Financial Corp cut its stake in shares of Genesis Energy, L.P. common stock (NYSE:GEL) by 1.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 450,749 shares of the pipeline company’s stock after selling 7,788 shares during the quarter. Stifel Financial Corp owned about 0.37% of Genesis Energy, L.P. common stock worth $8,884,000 as of its most recent SEC filing.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Genesis Energy, L.P. common stock (GEL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Blair William & Co. IL cut its stake in Genesis Energy, L.P. common stock (NYSE:GEL) by 21.6% in the first quarter, HoldingsChannel.com reports. The fund owned 55,817 shares of the pipeline company’s stock after selling 15,409 shares during the period. Blair William & Co. IL’s holdings in Genesis Energy, L.P. common stock were worth $1,100,000 as of its most recent filing with the Securities and Exchange Commission.
Top 10 Medical Stocks To Invest In Right Now: Compass Diversified Holdings(CODI)
Advisors’ Opinion:
- [By Ethan Ryder]
Schroder Investment Management Group grew its stake in Compass Diversified Holdings (NYSE:CODI) by 3.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,097,576 shares of the financial services provider’s stock after purchasing an additional 33,776 shares during the period. Schroder Investment Management Group owned approximately 1.83% of Compass Diversified worth $18,000,000 at the end of the most recent reporting period.
Top 10 Medical Stocks To Invest In Right Now: Inogen, Inc(INGN)
Advisors’ Opinion:
- [By Shane Hupp]
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
Get Inogen alerts:
Comparing Halyard Health (HYH) and Inogen (INGN) (americanbankingnews.com) ‘The stock market has sucked on nitrous oxide’ Wall… (beaumontenterprise.com) EPS Calculations to Consider Inogen Inc (NASDAQ: INGN) (stocksmarketcap.com) Inogen’s shares drop on short seller Citron’s tweet (reuters.com) Inogen Hit By Citron Report; Analyst Rebuttal Calls This ‘An Excellent Entry Point’ (msn.com)
Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Inogen from $150.00 to $180.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 1st. Leerink Swann restated an “outperform” rating and set a $170.00 price target (up from $150.00) on shares of Inogen in a research report on Tuesday, May 1st. ValuEngine upgraded Inogen from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a research report on Tuesday, February 13th. Finally, BidaskClub upgraded Inogen from a “hold” rating to a “buy” rating in a research report on Friday, March 9th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and three have issued a strong buy rating to the company. Inogen has an average rating of “Buy” and an average target price of $178.00.
- [By Ethan Ryder]
Inogen Inc (NASDAQ:INGN) Director Ray Benjamin M. Anderson sold 1,000 shares of the company’s stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $184.88, for a total value of $184,880.00. Following the completion of the transaction, the director now owns 1,989 shares in the company, valued at $367,726.32. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
- [By Logan Wallace]
Rock Springs Capital Management LP lifted its stake in shares of Inogen Inc (NASDAQ:INGN) by 38.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 110,500 shares of the medical technology company’s stock after purchasing an additional 30,500 shares during the quarter. Rock Springs Capital Management LP owned 0.52% of Inogen worth $13,574,000 as of its most recent SEC filing.
- [By Logan Wallace]
Inogen Inc (NASDAQ:INGN) EVP Byron Myers sold 1,846 shares of the business’s stock in a transaction dated Monday, June 18th. The stock was sold at an average price of $190.04, for a total transaction of $350,813.84. Following the sale, the executive vice president now owns 39,121 shares in the company, valued at $7,434,554.84. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Top 10 Medical Stocks To Invest In Right Now: RELX N.V.(RENX)
Advisors’ Opinion:
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Relx (RENX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 10 Medical Stocks To Invest In Right Now: American Financial Group, Inc.(AFG)
Advisors’ Opinion:
- [By Ethan Ryder]
Media headlines about American Financial Group (NYSE:AFG) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. American Financial Group earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned press coverage about the insurance provider an impact score of 46.840441381164 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
- [By Joseph Griffin]
Westpac Banking Corp increased its stake in shares of American Financial Group (NYSE:AFG) by 10.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,403 shares of the insurance provider’s stock after purchasing an additional 709 shares during the quarter. Westpac Banking Corp’s holdings in American Financial Group were worth $831,000 as of its most recent filing with the SEC.
- [By Shane Hupp]
Get a free copy of the Zacks research report on American Financial Group (AFG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 10 Medical Stocks To Invest In Right Now: OneMain Holdings, Inc.(OMF)
Advisors’ Opinion:
- [By Max Byerly]
Rhumbline Advisers boosted its position in shares of OneMain Holdings Inc (NYSE:OMF) by 18.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 59,772 shares of the financial services provider’s stock after acquiring an additional 9,479 shares during the period. Rhumbline Advisers’ holdings in OneMain were worth $1,790,000 as of its most recent filing with the Securities & Exchange Commission.
- [By Max Byerly]
OneMain (NYSE: OMF) and Provident Financial (OTCMKTS:FPLPY) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.
- [By Shane Hupp]
Get a free copy of the Zacks research report on OneMain (OMF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 10 Medical Stocks To Invest In Right Now: SPDR S&P Biotech ETF (XBI)
Advisors’ Opinion:
- [By ]
In a sea of red, small-cap biotech stocks stood strong during Wednesdays trading session. The SPDR S&P Biotech ETF (NYSE:XBI) finished the day higher by more than 1.25% while the Nasdaq Composite was stuck in the red. XBIs comeback rally that began to materialize just before Christmas is now threatening to break out to new highs.
- [By Money Morning News Team]
But the biotech sector crushed the market, with the SPDR S&P Biotech ETF (NYSE: XBI) returning a market-beating 43.36% in 2017, nearly double the broader S&P 500.
- [By Jim Crumly]
Technology was the weakest sector, with biotech and semiconductor stocks in particular having a tough day. TheSPDR S&P Biotech ETF (NYSEMKT:XBI) tumbled 3.2% and theiShares PHLX Semiconductor ETF (NASDAQ:SOXX) lost 2.4%.
- [By ]
More importantly, the SPDR S&P Biotech ETF (NYSE:XBI) has proven resilient during the volatility spike and selloff.
In fact, XBI never closed significantly below its 50-day moving average as investors dumped stocks. That turned out to be a huge tell
Top 10 Medical Stocks To Invest In Right Now: Energy Fuels Inc(UUUU)
Advisors’ Opinion:
- [By Logan Wallace]
Old West Investment Management LLC purchased a new stake in Energy Fuels Inc (NYSEAMERICAN:UUUU) (TSE:EFR) in the first quarter, HoldingsChannel reports. The firm purchased 578,496 shares of the basic materials company’s stock, valued at approximately $1,003,000.
- [By Stephan Byrd]
Energy Fuels (NYSEAMERICAN:UUUU) (TSE:EFR) shares saw an uptick in trading volume on Monday . 1,091,365 shares were traded during mid-day trading, an increase of 300% from the previous session’s volume of 272,846 shares.The stock last traded at $2.09 and had previously closed at $2.04.
- [By Stephan Byrd]
Energy Fuels Inc (NYSEAMERICAN:UUUU) (TSE:EFR) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 2,265,513 shares, an increase of 19.6% from the May 31st total of 1,893,582 shares. Based on an average daily volume of 589,166 shares, the days-to-cover ratio is presently 3.8 days. Approximately 3.3% of the shares of the stock are short sold.
